• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Eli Lilly & Co.

Evox Therapeutics completes $95.4M Series C

February 18, 2021 By Sean Whooley Leave a Comment

Evox Therapeutics announced today that it raised $95.4 million (£69.2 million) in a Series C financing round. Oxford, England-based Evox’s financing was significantly oversubscribed with high demand from both existing and new investors, according to a news release. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Funding Roundup, Pharmaceutical Tagged With: Eli Lilly & Co., evoxtherapeutics, Takeda Pharmaceuticals

FDA authorizes Eli Lilly’s monoclonal antibody treatment for COVID-19

February 10, 2021 By Sean Whooley

The FDA announced that it issued emergency use authorization (EUA) for monoclonal antibodies developed by Eli Lilly (NYSE:LLY) for treating COVID-19. Eli Lilly’s bamlanivimab and etesevimab received authorization to be administered together for treating mild to moderate COVID-19 in adults and pediatric patients over 12 years old and weighing at least 40 kilograms (about 88 pounds), according […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, Eli Lilly & Co., FDA

NIAID halts Lilly COVID-19 antibody study

October 27, 2020 By Nancy Crotti

An arm of NIH has ended a clinical trial investigating the use of Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab) to treat hospitalized COVID-19 patients. While the drug shows promise in treating mild-to-moderate COVID-19 infections, the ACTIV-3 trial involving severe cases of the disease showed little benefit, according to the National Institute of Allergy and Infectious Diseases […]

Filed Under: Business/Financial News, Clinical Trials Tagged With: coronavirus, COVID-19, Eli Lilly & Co., National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Report: Eli Lilly halts COVID-19 treatment trial

October 13, 2020 By Sean Whooley

Eli Lilly (NYSE:LLY) reportedly paused a clinical trial testing its COVID-19 antibody treatment candidate because of a “potential safety concern.” The New York Times reported that Eli Lilly’s testing site researchers were notified of the pause by emails sent by government officials (it is a government-sponsored trial) and the company later confirmed it. A spokesperson from the […]

Filed Under: Clinical Trials, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Eli Lilly & Co.

Dexcom, Lilly partner on diabetes management for healthcare providers

October 7, 2020 By Nancy Crotti

Eli Lilly (NYSE:LLY) and Dexcom (NSDQ:DXCM) today announced a joint program for U.S. healthcare providers that includes Lilly’s new, rapid-acting Lyumjev mealtime insulin pen and Dexcom G6 continuous glucose monitoring (CGM) systems. The program is designed to help clinicians use data to inform diabetes management, including promoting  the benefits of a new mealtime insulin dose, the companies said […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations Tagged With: Dexcom, Eli Lilly & Co.

The most innovative pharmaceutical agents of 2020

August 3, 2020 By Danielle Kirsh

The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, […]

Filed Under: Cardiovascular, Featured, Neurological, Oncology, Pharmaceutical Tagged With: AbbVie, Adlon Therapeutics, Advanced Accelerator Applications, Astellas Pharma, Bayer, Eli Lilly & Co., Galien Foundation, Genentech, Greenwich Biosciences, GW Pharmaceuticals, Janssen Biotech, Johnson & Johnson, Karyopharm Therapeutics, Medicines Development for Global Health, Merck, Novartis, Pfizer, Population Council, Purdue Pharma, Roche Group, Servier Pharmaceuticals, SIGA Technologies, Sobi, TB Alliance, Theravance Biopharma

AbbVie gains U.S. nod for $63B Allergan takeover

May 6, 2020 By Nancy Crotti

Pharmaceutical giant  AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its  purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: AbbVie, Allergan, AstraZeneca plc, Eli Lilly & Co., Federal Trade Commission (FTC), Johnson & Johnson

Clinical trials ramping up for potential coronavirus-fighting drugs

April 13, 2020 By Sean Whooley

Bausch Health (NYSE:BHC) announced today that it initiated a clinical trial program in Canada to investigate the use of Virazole for treating COVID-19. With today’s announcement, Bausch joins Eli Lilly (NYSE:LLY) and Care Access Research, which both announced clinical testing of coronavirus therapies last week. Bausch’s Virazole is currently approved in the U.S. and Canada, among other […]

Filed Under: Business/Financial News, Clinical Trials, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: bauschhealth, Care Access Research, coronavirus, COVID-19, Eli Lilly & Co., FDA

Lilly to integrate DexCom CGMs in automated dosing system

December 16, 2019 By Sean Whooley

Eli Lilly (NYSE:LLY) announced that it will integrate Dexcom (NSDQ:DXCM) products into its personalized diabetes management system, now under development. Under the new, non-exclusive agreement, Indianapolis-based Lilly will use San Diego-based Dexcom’s continuous glucose monitoring (CGM) devices in pen-based and pump-based platforms in Lily’s diabetes management system. The pen-based platform is designed to integrate personalized data from […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Dexcom, Eli Lilly & Co.

Eli Lilly, Aptar win FDA approval for nasal glucagon powder

July 25, 2019 By Brad Perriello

Eli Lilly (NYSE:LLY) and AptarGroup (NYSE:ATR) today won FDA approval for the first injection-free glucagon for treating severe low blood sugar in diabetes patients. The federal safety watchdog’s approval, of Lilly’s Baqsimi nasal powder and the delivery device developed by Aptar for treating severe hypoglycemia, was based on two studies comparing a single dose of Baqsimi […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: aptarpharma, Eli Lilly & Co.

Cigna lowers insulin price to $25 per month

April 3, 2019 By Nancy Crotti

Under pressure from patients and the FDA, Cigna (NYSE:CI) and Express Scripts said today that they will lower the price of insulin to $25 per month for some patients. Three firms — Eli Lilly, Novo Nordisk and Sanofi — control 90% of the global insulin market and produce all the insulin used in the U.S. […]

Filed Under: Business/Financial News, Diabetes, Featured, Food & Drug Administration (FDA), News Well, Pharmaceutical, Regulatory/Compliance Tagged With: Cigna, Eli Lilly & Co., Express Scripts, FDA, Novo Nordisk, Sanofi

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS